Is PFE stock a Buy, Sell, or Hold?

Based on our analysis, PFE is currently a WAIT with low confidence. 📊 MIXED SIGNALS: PFE shows conflicting indicators. Wait for confirmation before entering.

What is the fair value of PFE stock?

Our analysis estimates the fair value range for PFE to be between $27.61 and $29.13. The current price is $30.30.

What is the analyst price target for PFE?

The average Wall Street analyst price target for PFE is $29.26. This implies a potential upside of -2.0% from current levels.

Pfizer (PFE) Stock: Buy, Sell, or Hold?

PFE - Pfizer Inc.

PHARMACEUTICAL PREPARATIONS

$30.30

0.45 (1.49%) ▲

5d: +2.9%

30d: +7.51%

90d: +23.45%

WAIT

LOW Confidence

Protect Your PFE Gains

Analysis Updated: Oct 21, 2026 12:00 AM ET

Earnings: Nov 03, 2026 11d

Smart Money Distribution

Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →

Signal fired Oct 2, 2026 at $27.80 · last confirmed Oct 19, 2026

Strength: 9.0/10

Get Alerted When PFE Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 MIXED SIGNALS: PFE shows conflicting indicators. Wait for confirmation before entering.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: -2.5%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$27.53

Based on 0.8% avg growth

INTRINSIC VALUE TODAY

$17.09

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.2x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: PFE is currently trading at $30.30, which is considered extended relative to its 30-day fair value range of $27.61 to $29.13. From a valuation perspective, the stock is trading at a premium (Forward PE: 10.3) compared to its historical average (9.2). At these levels, the market is pricing in 4.0% annual earnings growth.

Technical Outlook: Technically, PFE is in a strong uptrend. The price is approaching resistance at $30.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: PFE scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED

Historical Trading Range $27.61 - $29.13

Company Quality Score 41/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 27.1%

Protect Your Profits

Holding PFE? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BEARISH: Price extended above range
BEARISH: Weak technical setup (0/100)
BULLISH: High volume confirmation
NEUTRAL: Near Wall St target ($29.26)
BULLISH: Expecting earnings turnaround to 4.0% growth with 2.6% revenue growth
WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $27.61 - $29.13

Current vs Trading Range EXTENDED

Support & Resistance Levels

Support Level $27.48

Resistance Level $30.25

Current Trend Strong Uptrend

Technical data as of Oct 21, 2026

Fundamental Context

Forward P/E (Next Year Est.) 10.34

Wall Street Target $29.26 (-2.0%)

Revenue Growth (YoY) 2.6%

Earnings Growth (YoY) -10.1%

Profit Margin 6.8%

Valuation Premium vs History +4.0% premium

PE vs Historical 10.3 vs 9.2 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): +4.0% (market-implied from PE analysis)

1-Year Target $31.04 (+4%)

2-Year Target $32.29 (+8%)

3-Year Target $33.58 (+13%)

3-Yr Target (if PE normalizes) (PE: 10→9) PE COMPRESSION $29.87 (+0%)

Earnings growth offset by PE compression

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 19.9, Growth: -2.5%) $53.19 (+78%)

Base: (SPY PE: 10.3, Growth: -2.5%) $27.70 (-7%)

Bear: (PE: 8.8, Growth: -2.5%) $23.54 (-21%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (40x PE), but valuation improves significantly next year (10x PE) as earnings recover.

Trailing PE: 39.62 | Current EPS (TTM): $0.76

Bull Case $66.24 (+122%)

Analyst growth 100.0%, PE expands to 43.6

Base Case $60.22 (+102%)

Market implied 100.0%, PE stable at 39.6

Bear Case $20.47 (-31%)

Severe decline -20.0%, PE contracts to 33.7

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: October 22, 2026 10:12 AM ET
Data refreshes hourly during market hours. Next update: 11:12 AM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is PFE showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for PFE.

Create Free Account

Already have an account? Log In

Featured in Portfolios

PFE is a key holding in these high-performance investment strategies.

Healthcare Giants Sector • +26.3% Return

View All Strategies

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
ABBV AbbVie Inc	STRONG BUY 30 analysts	$283	48 HOLD
LLY Eli Lilly and Company	STRONG BUY 31 analysts	$1328	36 SELL
GILD Gilead Sciences Inc	STRONG BUY 28 analysts	$160	42 HOLD
BIIB Biogen Inc	BUY 36 analysts	$244	43 HOLD
MRK Merck & Company Inc	STRONG BUY 27 analysts	$158	50 HOLD

ABBV AbbVie Inc

48 HOLD

LLY Eli Lilly and Com…

36 SELL

GILD Gilead Sciences I…

42 HOLD

BIIB Biogen Inc

43 HOLD

MRK Merck & Company I…

50 HOLD

Advanced PFE Option Strategies

Professional options setups generated by AI based on today's PFE price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for PFE

PFE Technical Chart PFE Price Prediction PFE Earnings Date PFE Investment Advisor PFE Fair Price Analyzer PFE Options Advisor PFE Options Chain PFE Options Analysis PFE Competitors

Compare PFE with Peers

PFE vs JNJ
Which one to buy?

PFE vs MRK
Which one to buy?

PFE vs XOM
Which one to buy?

PFE vs VZ
Which one to buy?

PFE vs JPM
Which one to buy?

TRDA vs PFE
Winner: PFE

IBIO vs PFE
Winner: PFE

ABT vs PFE
Winner: PFE

XRTX vs PFE
Winner: Tie

MRUS vs PFE

Create New Comparison View All Competitors

Tradestie